DLVR Therapeutics is developing an innovative, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system, initially for RNAi therapeutics.
DLVR Therapeutics is developing an innovative, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system, initially for RNAi therapeutics.
Ascletis is a biotech company dedicated to discovering and developing new treatments against cancer and infectious diseases using RNAi biotechnology.